Atlas Trials

Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.

Clinical trial NCT06327178 · RECRUITING

Trial details

NCT number
NCT06327178
Sponsor
Nanfang Hospital, Southern Medical University
Status
RECRUITING
Study type
OBSERVATIONAL
Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC
Start date
2023-10-01
Primary completion
2025-04-30
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.